Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017

  • ID: 4318709
  • Report
  • 146 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acucela Inc
  • Astellas Pharma Inc
  • GenSight Biologics SA
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • ReNeuron Group Plc
  • MORE
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 2, 22 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 1 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acucela Inc
  • Astellas Pharma Inc
  • GenSight Biologics SA
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • ReNeuron Group Plc
  • MORE
  1. Introduction
  2. Retinitis Pigmentosa (Retinitis) - Overview
  3. Retinitis Pigmentosa (Retinitis) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
  15. Acucela Inc
  16. Allergan Plc
  17. Amarantus Bioscience Holdings Inc
  18. Amgen Inc
  19. Applied Genetic Technologies Corp
  20. Asklepios BioPharmaceutical Inc
  21. Astellas Pharma Inc
  22. Caladrius Biosciences Inc
  23. Dompe Farmaceutici SpA
  24. GenSight Biologics SA
  25. Grupo Ferrer Internacional SA
  26. ID Pharma Co Ltd
  27. InFlectis BioScience
  28. Ionis Pharmaceuticals Inc
  29. M's Science Corp
  30. Mimetogen Pharmaceuticals Inc
  31. Nanovector srl
  32. Novartis AG
  33. Novelion Therapeutics Inc
  34. ProQR Therapeutics NV
  35. ReNeuron Group Plc
  36. SanBio Inc
  37. Sanofi
  38. Shire Plc
  39. Spark Therapeutics Inc
  40. Sun Pharma Advanced Research Company Ltd
  41. Retinitis Pigmentosa (Retinitis) - Drug Profiles
  42. A-004 - Drug Profile
  43. AMRS-001 - Drug Profile
  44. Antibodies to Antagonize IL-6 for Retinitis - Drug Profile
  45. AP-1 - Drug Profile
  46. BNP-RP - Drug Profile
  47. cenegermin - Drug Profile
  48. CPK-850 - Drug Profile
  49. cutamesine - Drug Profile
  50. FAB-111 - Drug Profile
  51. Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile
  52. Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile
  53. Gene Therapy for Ocular Diseases - Drug Profile
  54. Gene Therapy for Retinitis Pigmentosa - Drug Profile
  55. Gene Therapy for Retinitis Pigmentosa - Drug Profile
  56. Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile
  57. Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile
  58. Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile
  59. Gene Therapy to Activate mVChR1 for Retinits Pigmentosa - Drug Profile
  60. Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile
  61. Gene Therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile
  62. Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile
  63. GS-030 - Drug Profile
  64. GT-038 - Drug Profile
  65. HORAPDE-6B - Drug Profile
  66. HORARLBP-1 - Drug Profile
  67. IFB-088 - Drug Profile
  68. IONISRHO-2.5Rx - Drug Profile
  69. KIRA-6 - Drug Profile
  70. KUS-187 - Drug Profile
  71. LPDF-003 - Drug Profile
  72. myriocin - Drug Profile
  73. N-acetyl cysteine amide - Drug Profile
  74. NT-501 - Drug Profile
  75. OCU-100 - Drug Profile
  76. QRX-411 - Drug Profile
  77. ReN-003 - Drug Profile
  78. RST-001 - Drug Profile
  79. SAR-421869 - Drug Profile
  80. SB-623 - Drug Profile
  81. SHP-630 - Drug Profile
  82. Small Molecule for Retinitis Pigmentosa - Drug Profile
  83. Small Molecules for CNS Disorders and Ophthalmology - Drug Profile
  84. Small Molecules to Block Cyclic Nucleotide Gated Channel for Retinitis Pigmentosa - Drug Profile
  85. Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile
  86. STC-1 - Drug Profile
  87. Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile
  88. Stem Cell Therapy for Ophthalmic Disorders - Drug Profile
  89. Stem Cell Therapy for Retinitis Pigmentosa - Drug Profile
  90. Stem Cell Therapy for Retinitis Pigmentosa and Age Related Macular Degeneration - Drug Profile
  91. Stem Cell Therapy to Activate RPGR for Retinitis Pigmentosa - Drug Profile
  92. voretigene neparvovec - Drug Profile
  93. zuretinol acetate - Drug Profile
  94. Retinitis Pigmentosa (Retinitis) - Dormant Projects
  95. Retinitis Pigmentosa (Retinitis) - Discontinued Products
  96. Retinitis Pigmentosa (Retinitis) - Product Development Milestones
  97. Featured News & Press Releases
  98. Appendix
  99. Methodology
  100. Coverage
  101. Secondary Research
  102. Primary Research
  103. Expert Panel Validation
  104. Contact Us
  105. Disclaimer
List of Tables
  1. Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Companies, H1 2017 (Contd..1), H1
  4. Number of Products under Development by Universities/Institutes, H1
  5. Products under Development by Companies, H1
  6. Products under Development by Companies, H1 2017 (Contd..1), H1
  7. Products under Development by Companies, H1 2017 (Contd..2), H1
  8. Products under Development by Universities/Institutes, H1
  9. Number of Products by Stage and Target, H1
  10. Number of Products by Stage and Mechanism of Action, H1
  11. Number of Products by Stage and Route of Administration, H1
  12. Number of Products by Stage and Molecule Type, H1
  13. Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H1
  14. Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H1
  15. Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings Inc, H1
  16. Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H1
  17. Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H1
  18. Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical Inc, H1
  19. Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc, H1
  20. Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences Inc, H1
  21. Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H1
  22. Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H1
  23. Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional SA, H1
  24. Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co Ltd, H1
  25. Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H1
  26. Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals Inc, H1
  27. Retinitis Pigmentosa (Retinitis) - Pipeline by M's Science Corp, H1
  28. Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc, H1
  29. Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector srl, H1
  30. Retinitis Pigmentosa (Retinitis) - Pipeline by Novartis AG, H1
  31. Retinitis Pigmentosa (Retinitis) - Pipeline by Novelion Therapeutics Inc, H1
  32. Retinitis Pigmentosa (Retinitis) - Pipeline by ProQR Therapeutics NV, H1
  33. Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H1
  34. Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio Inc, H1
  35. Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H1
  36. Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H1
  37. Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics Inc, H1
  38. Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1
  39. Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1
  40. Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2017 (Contd..1), H1
  41. Retinitis Pigmentosa (Retinitis) - Discontinued Products, H1
List of Figures
  1. Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Top 10 Targets, H1
  5. Number of Products by Stage and Top 10 Targets, H1
  6. Number of Products by Top 10 Mechanism of Actions, H1
  7. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  8. Number of Products by Routes of Administration, H1
  9. Number of Products by Stage and Routes of Administration, H1
  10. Number of Products by Molecule Types, H1
  11. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acucela Inc
  • Allergan Plc
  • Amarantus Bioscience Holdings Inc
  • Amgen Inc
  • Applied Genetic Technologies Corp
  • Asklepios BioPharmaceutical Inc
  • Astellas Pharma Inc
  • Caladrius Biosciences Inc
  • Dompe Farmaceutici SpA
  • GenSight Biologics SA
  • Grupo Ferrer Internacional SA
  • ID Pharma Co Ltd
  • InFlectis BioScience
  • Ionis Pharmaceuticals Inc
  • M's Science Corp
  • Mimetogen Pharmaceuticals Inc
  • Nanovector srl
  • Novartis AG
  • Novelion Therapeutics Inc
  • ProQR Therapeutics NV
  • ReNeuron Group Plc
  • SanBio Inc
  • Sanofi
  • Shire Plc
  • Spark Therapeutics Inc
  • Sun Pharma Advanced Research Company Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll